MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
VolitionRx Limited Market Cap 2011-2026 | VNRX
As of April 13, 2026 VolitionRx Limited has a market cap of $ 21.4 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.2 M | 54.8 M | 58.1 M | 89.1 M | 157 M | 200 M | 185 M | 79.7 M | 92.6 M | 107 M | 66.8 M | 67.2 M | 27.1 M | 23.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 23.4 M | 88.1 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Agilent Technologies
A
|
42 B | $ 115.06 | -0.29 % | $ 35 B |  USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
7.95 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M |  Israel |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
993 M | $ 16.05 | -3.83 % | $ 855 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
5.85 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Exact Sciences Corporation
EXAS
|
19.5 B | - | - | $ 19.8 B | USA |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
Interpace Biosciences
IDXG
|
7.34 M | $ 2.3 | - | $ 10.2 M | USA |
 |
Charles River Laboratories International
CRL
|
7.69 B | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
150 B | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Medpace Holdings
MEDP
|
13 B | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Illumina
ILMN
|
16.4 B | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
Myriad Genetics
MYGN
|
409 M | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
NeoGenomics
NEO
|
1.48 B | $ 7.69 | -3.17 % | $ 985 M | USA |
 |
Guardant Health
GH
|
13.4 B | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
8.52 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
104 K | $ 2.69 | -1.82 % | $ 87.3 K | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Invitae Corporation
NVTA
|
511 M | - | - | $ 21.2 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
30.8 B | $ 28.31 | 0.62 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
23.9 B | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
5.31 B | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
5.37 B | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
5.12 B | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Quest Diagnostics Incorporated
DGX
|
23.3 B | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
ENDRA Life Sciences
NDRA
|
3.66 M | $ 4.94 | -6.97 % | $ 3.89 M | USA |
 |
Organovo Holdings
ONVO
|
3.1 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.12 M | - | -16.95 % | $ 1.54 M | USA |
 |
National Research Corporation
NRC
|
315 M | $ 16.48 | -3.34 % | $ 369 M | USA |